Clinically targeted screening for congenital CMV - potential for integration into the National Hearing Screening Programme
| Autor: | Janet E. Berrington, Seilesh Kadambari, Adrian Davis, Suzanne Luck, Eleri J Williams, Mike Sharland, Paul D. Griffiths |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Ganciclovir
Pediatrics medicine.medical_specialty Hearing loss Hearing Loss Sensorineural Antiviral Agents State Medicine Hearing screening Screening programme Neonatal Screening otorhinolaryngologic diseases medicine Humans Targeted screening Congenital cmv business.industry Infant Newborn General Medicine medicine.disease United Kingdom Early Diagnosis Cytomegalovirus Infections Pediatrics Perinatology and Child Health Feasibility Studies Sensorineural hearing loss medicine.symptom business medicine.drug |
| Zdroj: | Acta Paediatrica. 102:928-933 |
| ISSN: | 0803-5253 |
| DOI: | 10.1111/apa.12335 |
| Popis: | UNLABELLED Screening for a condition should only be undertaken if certain strict criteria are met. Congenital CMV (cCMV) is a leading cause of sensorineuronal hearing loss (SNHL) and meets many of these criteria, but is not currently screened for in the UK. Ganciclovir reduces CMV-induced progressive SNHL if treatment is begun in the first month of life. The Newborn Hearing Screening Programme (NHSP) has been shown to identify SNHL at the earliest possible age. The potential of integrating screening for cCMV into the NHSP is discussed to consolidate the link between screening, early diagnosis and management. CONCLUSION The early diagnosis and treatment of cCMV may prevent a small proportion of late SNHL. In the absence of any screening programme, we provide evidence that clinically targeted screening through the NHSP is a potential option in the UK, enhancing the diagnostic pathway and enabling appropriate early treatment to reduce long-term morbidity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text